Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,309,824
  • Shares Outstanding, K 1,476,673
  • Annual Sales, $ 33,266 M
  • Annual Income, $ 7,882 M
  • 60-Month Beta 0.83
  • Price/Sales 3.28
  • Price/Cash Flow 7.14
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 2.25
  • Number of Estimates 3
  • High Estimate 2.31
  • Low Estimate 2.15
  • Prior Year 2.14
  • Growth Rate Est. (year over year) +5.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.55 +16.18%
on 03/23/20
91.86 -20.89%
on 03/04/20
-12.75 (-14.93%)
since 02/27/20
3-Month
62.55 +16.18%
on 03/23/20
97.86 -25.74%
on 02/12/20
-16.53 (-18.53%)
since 12/27/19
52-Week
62.55 +16.18%
on 03/23/20
97.86 -25.74%
on 02/12/20
-7.22 (-9.04%)
since 03/27/19

Most Recent Stories

More News
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia

The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.

PFE : 30.90 (-2.68%)
LLY : 134.11 (-0.18%)
BMY : 52.79 (+1.03%)
ABBV : 72.67 (-1.57%)
Will Rescue Deal Impact Last? 4 Coronavirus-Proof Dividend Picks

With the ongoing erratic movement of most stocks, it's a prudent idea for investors to go for dividend-paying stocks as a regular source of income.

MDT : 89.89 (-2.23%)
WYNN : 63.31 (-11.47%)
STZ : 144.88 (+2.98%)
QCOM : 66.59 (-3.46%)
FB : 156.79 (-4.01%)
ABBV : 72.67 (-1.57%)
NCLH : 12.02 (-23.49%)
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia

The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.

AZN : 42.47 (+0.26%)
PFE : 30.90 (-2.68%)
ABBV : 72.67 (-1.57%)
FGEN : 33.47 (-1.03%)
AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $67.91, moving +0.62% from the previous trading session.

ABBV : 72.67 (-1.57%)
Coronavirus Drug Development Race to Boost These 4 Stocks

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

REGN : 449.52 (-0.61%)
GILD : 72.85 (-1.37%)
MRNA : 30.05 (+7.55%)
ABBV : 72.67 (-1.57%)
INO : 8.32 (+16.36%)
VXRT : 1.7400 (+2.35%)
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

BMY : 52.79 (+1.03%)
AMGN : 198.27 (-0.11%)
ABBV : 72.67 (-1.57%)
CTMX : 6.35 (-1.40%)
The Extreme Risks of Trading Your Own Retirement Assets - March 25, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ABBV : 72.67 (-1.57%)
RTN : 142.02 (-8.49%)
SASR : 22.26 (-5.03%)
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - March 24, 2020

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate...

ABBV : 72.67 (-1.57%)
AZN : 42.47 (+0.26%)
BBY : 62.47 (-0.65%)
Top Ranked Income Stocks to Buy for March 24th

Top Ranked Income Stocks to Buy for March 24th

NRZ : 6.88 (-5.23%)
DUK : 80.19 (-1.23%)
ABBV : 72.67 (-1.57%)
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive...

BIIB : 296.75 (-2.69%)
JNJ : 123.16 (-2.69%)
RHHBY : 38.9650 (+0.48%)
ABBV : 72.67 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 77.16
1st Resistance Point 74.92
Last Price 72.67
1st Support Level 70.57
2nd Support Level 68.46

See More

52-Week High 97.86
Fibonacci 61.8% 84.37
Fibonacci 50% 80.21
Fibonacci 38.2% 76.04
Last Price 72.67
52-Week Low 62.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar